EGF at 1 μM in MDA-MB 231 and p<0.01 vs. EGF at 2.5 μM in primary breast cancer cells) suggesting that it acts by antagonising EGF action in inhibiting proliferation of these cells. This evidence concerns the gene EGF and breast carcinoma.